CIBC Bancorp USA’s Lineage Cell Therapeutics LCTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$21K Buy
22,018
+11,844
+116% +$13.1K ﹤0.01% 2218
2026
Q2
$13.3K Buy
+10,174
New +$14.1K ﹤0.01% 1925

Other funds holding LCTX

CIBC Bancorp USA's LCTX Position: Q3 2026 in Review

CIBC Bancorp USA increased its Lineage Cell Therapeutics (LCTX) stake by 116% in Q3 2026, buying an estimated $13.1K and bringing the position to 22,018 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #2218.

CIBC Bancorp USA first reported a position in LCTX in Q2 2026 and has held it in 2 quarters since. 143 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

  • CIBC Bancorp USA held 22,018 shares of Lineage Cell Therapeutics worth $21K as of Q3 2026.
  • CIBC Bancorp USA bought 11,844 Lineage Cell Therapeutics shares in Q3 2026, an estimated $13.1K.
  • Lineage Cell Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #2218 holding.
  • CIBC Bancorp USA first reported a position in Lineage Cell Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 143 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.